🇺🇸 Hydrochlorothiazide (HCT) in United States
12 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 12
Most-reported reactions
- Gastrointestinal Haemorrhage — 2 reports (16.67%)
- Pruritus — 2 reports (16.67%)
- Anaemia — 1 report (8.33%)
- Anaphylactic Shock — 1 report (8.33%)
- Angioedema — 1 report (8.33%)
- Blood Urine Present — 1 report (8.33%)
- Bone Marrow Depression — 1 report (8.33%)
- Bronchitis Chronic — 1 report (8.33%)
- Cardiac Failure — 1 report (8.33%)
- Cerebrovascular Accident — 1 report (8.33%)
Other Cardiovascular approved in United States
Frequently asked questions
Is Hydrochlorothiazide (HCT) approved in United States?
Hydrochlorothiazide (HCT) does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Hydrochlorothiazide (HCT) in United States?
Takeda is the originator. The local marketing authorisation holder may differ — check the official source linked above.